EDP 305

Drug Profile

EDP 305

Alternative Names: EDP-305

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary biliary cirrhosis
  • Phase I Non-alcoholic fatty liver disease

Most Recent Events

  • 09 Feb 2018 Phase-II clinical trials in Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (NCT03421431)
  • 05 Jan 2018 Phase-II clinical trials in Primary biliary cirrhosis in USA (NCT03394924)
  • 20 Nov 2017 EDP 305 receives Fast Track designation for Primary biliary cirrhosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top